Technology evaluation: SGN-15, Seattle Genetics Inc.
Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol-Myers Squibb (BMS) for the potential treatment of cancer, which is currently in phase II trials [283767], [305881], [391927]. BMS had licensed technology from Enzon to help antibodies such as SGN-15 penetrate tumors more efficiently [174538]. BMS also had an R&D agreement with Genzyme for the production of SGN-15 in transgenic goats milk [177921]. In 1993, Ixsys (now Applied Molecular Evolution Inc) and BMS entered into a three-year collaboration to apply Ixsys's molecular design technology to BMS's monoclonal antibody research [190662]. Seattle Genetics licensed SGN-15 from BMS in April 1999 [283767].
Smith
S
S
Suzanne_Smith162@hotmail.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C092612:BR96-doxorubicin immunoconjugate; D000922:Immunotoxins; D004317:Doxorubicin